CN105326889A - Medicine composition for treating malignant tumors and preparing method thereof - Google Patents

Medicine composition for treating malignant tumors and preparing method thereof Download PDF

Info

Publication number
CN105326889A
CN105326889A CN201510871934.7A CN201510871934A CN105326889A CN 105326889 A CN105326889 A CN 105326889A CN 201510871934 A CN201510871934 A CN 201510871934A CN 105326889 A CN105326889 A CN 105326889A
Authority
CN
China
Prior art keywords
weight portion
pharmaceutical composition
malignant tumor
treatment
crude drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201510871934.7A
Other languages
Chinese (zh)
Inventor
邵培财
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201510871934.7A priority Critical patent/CN105326889A/en
Publication of CN105326889A publication Critical patent/CN105326889A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine composition for treating malignant tumors and a preparing method thereof. The medicine composition is prepared from okanin, semen caesalpiniae cristae, caragana tibetica, leucocianidol, cichoriin and anonaine. The composition can be prepared into various dosage forms according to the conventional preparation technology, and the curative effect of treating the malignant tumors is remarkable.

Description

A kind of pharmaceutical composition for the treatment of malignant tumor and preparation method thereof
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of malignant tumor and preparation method thereof.
Background technology
Malignant tumor is the disease of serious threat human health, and sickness rate rises year by year in recent years, owing to lacking corresponding knowledge, all arrives middle and advanced stage, and then occur symptoms such as becoming thin, tired during many Finding case malignant tumor.TNF was found by Caswell early than 1975, TNF-α is separated in 1989 the 1st time by as the inhibiting tumor cell factor, mononuclear phagocyte primarily of activation produces, it is one of important medium participating in immunoreation and inflammatory reaction, there is indication of multiple local and system biological activity, multiple physiology, pathology and immunologic process can be participated in.Low-level TNF-α plays a part favourable in tissue repair, and discharge in a large number and can cause tissue injury, research shows that large absolutely number middle and terminal cancer patient all occurs that the exception of TNF-α raises, body can be made to produce hyperlipemia, fatty acid conversion ratio and lipolyse increase, muscle power and the equal Progressive symmetric erythrokeratodermia of weight under degradation cachexia sample symptom, often the state of an illness is heavier for the higher person of TNF-α.Therefore, detect the concentration of serum TNF-α during research treating malignant tumor, to the judgement of curative effect, also there is certain clinical meaning.The quality of life paid attention to and improve tumor patient is a very important developing trend in recent years, and be also one of therapeutic goal of modern oncology, be that doctor selects Therapeutic Method, assessment therapeutic effect, analyzes the important indicator of prognosis simultaneously.
Chinese medicine is thought, malignant tumor late period is that the positive deficiency of vital energy of body declines, Chinese medicine has unique advantage in treatment malignant tumor process, can at many levels, multipath, Mutiple Targets, multi-angle nurse one's health, focus on training and hold up body healthy energy, improve symptom and sign, improve patients ' life quality, extend life cycle, be one of characteristic of the anti-curing oncoma of China, occupy an important position in the Comprehensive Treatment of tumor.
Coreopsis basalis chalcone derivative (Okanin): CAS 484-76-4, molecular formula C 15h 12o 6, molecular weight 288.26.[pharmacological action] flavochrome.In [ingredient origin] Compositae golden pheasant Chrysanthemum and Bidens plant Hemerocallis citrina Baroni.
Ramulus seu Fructus Caesalpiniae: this product is the dry mature seed of leguminous plant Ramulus seu Fructus Caesalpiniae CaesalpiniacristaL..Gather during fruit maturation.[nature and flavor] are pungent, puckery, temperature.[function with cure mainly] the kidney warming, by cold.Sick for renal cold, cold syndrome of the stomach.[character] this product is irregular cycle, slightly flat, and some sides are truncate or have shallow depression, and surperficial celadon is smooth, and micro-tool gloss has proper alignment ring grain to prolong and top.There is point-like hilum one end, ivory buff or light yellowish brown, has the crineous ring grain of diameter 2 ~ 3mm around it.Matter is hard, after breaking, plants skin depth and is about 1mm, inner face yellowish white, have slightly protruding strain line; Cotyledon is oblate, yellow-white, and matter is hard, and there is irregular groove on surface, and section is slightly smooth.Feeble QI raw meat, bitter in the mouth.Record in health Tibetan medicine standard promulgated by the ministries or commissions of the Central Government (first), standard number: WS3-BC-0003-95
ZANGJINJIER: this product is the woody part heartwood of leguminous plant Cortes seu Caulis Caraganae jubatae Caraganajubata (pall.) Poir. and Changdu caragana Caraganachangduensisfiauf.Cut and get maroon woody part, cut off, dry in the shade.[nature and flavor] are puckery, cold.[function with cure mainly] removing blood stasis, blood stasis dispelling, blood pressure lowering.For high mountain plethora, vascular hypertension and menoxenia.[character] this product is the heartwood of the many Ex-alls of appearance cork, cylindrical or irregular block sheet, slightly bending, and long 20 ~ 40cm, diameter can reach 5cm.There is cutter axe mark on surface, smoothly, has the cicatrix of the thin vertical of buckling or reticular texture and sprig, the aobvious yellow-white wood grain had.The endothelium of the visible yellow-white in stem branch residue place and dark-brown phellem layer.Matter is hard and fine and close, and difficulty fractures.The visible annual ring of section.Odorless, lightly seasoned micro-peppery.Record in health Tibetan medicine standard promulgated by the ministries or commissions of the Central Government (first), standard number: WS3-BC-0134-95.
Leucocianidol (Leucocyanidin): CAS 69256-15-1, molecular formula C 15h 14o 7, molecular weight 306.27.[pharmacological action] blood sugar lowering, suppresses eye aldose reductase.[ingredient origin] polygonaceae plant greater membrane mould root, halberd folic acid film; Pulse family babul flower, shield post bean; Annonaceae; The plants such as Myrtaceae.
Cichoriin (Cichoriin): CAS 531-58-8, molecular formula C 15h 16o 9, molecular weight 340.29.[pharmacological action] antifeedant for insect.[ingredient origin] feverfew lettuce and artemisia, bachelor's-button, scorpion tail Chrysanthemum, the plants such as bolt fruit Chrysanthemum.
Anonaine (Anonaine): CAS 1862-41-5, molecular formula C 17h 15nO 2, molecular weight 265.31.[pharmacological action] expelling worm, antibacterial.[ingredient origin] annonaceae plant bullock's-heart, nymphaeaceae plant.
The chemical constitution of 4 crude drug is as follows:
Cichoriin (Cichoriin) Coreopsis basalis chalcone derivative (Okanin)
Leucocianidol (Leucocyanidin) anonaine (Anonaine).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment malignant tumor and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment malignant tumor are:
Coreopsis basalis chalcone derivative 120-140 weight portion Ramulus seu Fructus Caesalpiniae 100-120 weight portion ZANGJINJIER 80-100 weight portion leucocianidol 5-7 weight portion cichoriin 2-4 weight portion anonaine 2-3 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of malignant tumor, be made up of the crude drug of following weight portion:
Coreopsis basalis chalcone derivative 130 weight portion Ramulus seu Fructus Caesalpiniae 110 weight portion ZANGJINJIER 90 weight portion leucocianidol 6 weight portion cichoriin 3 weight portion anonaine 2.5 weight portion.
Treat a pharmaceutical composition for malignant tumor, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for malignant tumor, it is characterized in that the treatment malignant tumor medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of malignant tumor, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Coreopsis basalis chalcone derivative 120-140 weight portion Ramulus seu Fructus Caesalpiniae 100-120 weight portion ZANGJINJIER 80-100 weight portion leucocianidol 5-7 weight portion cichoriin 2-4 weight portion anonaine 2-3 weight portion;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Preferably treat a preparation method for the pharmaceutical composition of malignant tumor, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Coreopsis basalis chalcone derivative 130 weight portion Ramulus seu Fructus Caesalpiniae 110 weight portion ZANGJINJIER 90 weight portion leucocianidol 6 weight portion cichoriin 3 weight portion anonaine 2.5 weight portion;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Treat a preparation method for the pharmaceutical composition of malignant tumor, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of malignant tumor, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat malignant tumor medicine.
Adopt medicine composite for curing malignant tumor can improve the immunologic function of body preferably, the quality of life of tumor patient can be improved again, and safe and reliable, have no side effect.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of malignant tumor and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of malignant tumor are: Coreopsis basalis chalcone derivative 130g Ramulus seu Fructus Caesalpiniae 110g ZANGJINJIER 90g leucocianidol 6g cichoriin 3g anonaine 2.5g;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 2: pharmaceutical composition for the treatment of malignant tumor and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of malignant tumor are: Coreopsis basalis chalcone derivative 140g Ramulus seu Fructus Caesalpiniae 100g ZANGJINJIER 100g leucocianidol 5g cichoriin 4g anonaine 2g;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 3: pharmaceutical composition for the treatment of malignant tumor and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of malignant tumor are: Coreopsis basalis chalcone derivative 120g Ramulus seu Fructus Caesalpiniae 120g ZANGJINJIER 80g leucocianidol 7g cichoriin 2g anonaine 3g;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 100g, adds starch 50g, mixing, granulates, dry, adds microcrystalline Cellulose 21g, magnesium stearate 1.2g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 100g, adds starch 60g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1000.
Embodiment 6: the preparation of drop pill
Taking Macrogol 4000 150g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 30g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 5 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 1.5cm apart from liquid level, drips speed with per minute 60 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Embodiment 7: the pharmaceutical composition for the treatment of malignant tumor
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of malignant tumor are:
Coreopsis basalis chalcone derivative 129 weight portion leucocianidol 119 weight portion cichoriin 4 weight portion anonaine 2 weight portion.
Embodiment 8: the pharmaceutical composition for the treatment of malignant tumor
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of malignant tumor are:
Coreopsis basalis chalcone derivative 136 weight portion leucocianidol 2 weight portion cichoriin 4 weight portion anonaine 6 weight portion.
Embodiment 9: the pharmaceutical composition for the treatment of malignant tumor
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of malignant tumor are:
Coreopsis basalis chalcone derivative 123 weight portion leucocianidol 5 weight portion cichoriin 3 weight portion anonaine 1 weight portion.
Experimental example 1: the experimental study for the treatment of malignant tumor
1 data and method
Whole 160 examples of 1.1 physical data are our province geriatric hospital oncology outpatient service (92 example) and (68 example) patient that is in hospital, and are divided into two groups at random.Treatment group 80 example, man 42 example, female 38 example; 33 ~ 72 years old age, average 57 years old; Wherein pulmonary carcinoma 24 example, human primary gastrointestinal cancers 20 example, hepatocarcinoma 10 example, ovarian cancer 11 example, mammary cancer 10 example, other tumor 5 examples.Matched group 80 example, man 43 example, female 37 example; 33 ~ 72 years old age, average 56 years old; Wherein pulmonary carcinoma 24 example, human primary gastrointestinal cancers 20 example, hepatocarcinoma 10 example, ovarian cancer 11 example, mammary cancer 10 example, other tumor 5 examples.Two groups of physical data comparing difference not statistically significants (P > 0.05), have comparability.
1.2 diagnostic criterias are with reference to related content diagnosis in " Chinese Internal Medicine ", and all patients all make a definite diagnosis through histopathology or imaging examination.
1.3 Therapeutic Method
1.3.1 treatment group gives medicine composite for curing.Pharmaceutical composition is embodiment 1 pharmaceutical composition lot number 20121014.Every day 3 times, each 1g.
1.3.2 matched group adopts Radix Astragali injection (Zhengda Qingchunbao Pharmaceutical Co., Ltd, the accurate word Z33020179 of traditional Chinese medicines) 20mL, vitamin C injection ［ Shanghai Modern Hasen (Shangqiu) Pharmaceutical Co., Ltd., the accurate word H41024222 of traditional Chinese medicines ］ 2.0g, inosine in sodium chloride injection (Fuzhou Neptunus Fuyao Pharmaceuticals Co., Ltd., the accurate word H20030398 of traditional Chinese medicines) 0.4g, potassium chloride injection (Hebei Tiancheng Pharmaceutical Co., Ltd., the accurate word H13022128 of traditional Chinese medicines) 10mL adds in 5% glucose injection 500mL, 1 intravenous drip every day.
1.3.3 treat all continuously and add up curative effect after 30 days the course for the treatment of two groups.
The change of tumor necrosis factor-alpha (TNF-α) level before and after 1.4 observational technique observation and comparison 2 groups treatments, and the quality of life after treatment is evaluated.TNF-α adopts the full-automatic IMMULITE immunochemiluminometry instrument of DPC company of the U.S. to measure.Quality of life assessment is worked out quality of life in cancer patients according to European cancer research and treated tissue and is measured scale (EORTCQLQ-C30) project and evaluate.
1.5 statistical methods adopt SPSS15.0 statistical software to carry out statistical analysis, and measurement data mean ± standard deviation (x ± s) represents, adopt t inspection; The comparison of enumeration data rate adopts χ 2inspection.
2 results
Before and after 2.1 liang of group treatments, the change of TNF-alpha levels is compared in table 1.
Before and after table 1 liang group treatment, the change of TNF-alpha levels compares ng/L, x ± s
Group n Before treatment After treatment
Treatment group 80 12.77±4.24 8.07±4.54 ＊△
Matched group 80 12.65±4.18 12.18±4.97 *
With this group before treatment, *p < 0.05; Compare with after treatment of control group, △p < 0.05
From table 1, treating front TNF-alpha levels comparing difference with this group after two groups of treatments has statistical significance (P < 0.05); After two groups of treatments, between TNF-alpha levels group, comparing difference has statistical significance (P < 0.05), and treatment group TNF-alpha levels obviously reduces.
After 2.2 liang of group treatments, the scoring of EORTCQLQ-C30 scale project is compared in table 2.
From table 2, after 2 groups of treatments in EORTCQLQ-C30 scale somatic function, tired, feeling sick has statistical significance (P < 0.05) with vomiting, loss of appetite, constipation project comparing difference of marking, other project is marked the equal not statistically significant of comparing difference (P > 0.05).
After table 2 liang group treatment, the scoring of EORTC, QLQ-C30 scale project is compared
Compare with matched group, *p < 0.05.
2.3 untoward reaction are observed two groups and are all occurred without obvious adverse reaction over the course for the treatment of and after treatment.
This result of study shows, and adopts medicine composite for curing malignant tumor of the present invention can improve the immunologic function of body preferably, can improve again the quality of life of tumor patient, and safe and reliable, has no side effect, has broad application prospects in clinical.

Claims (8)

1. treat a pharmaceutical composition for malignant tumor, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Coreopsis basalis chalcone derivative 120-140 weight portion Ramulus seu Fructus Caesalpiniae 100-120 weight portion ZANGJINJIER 80-100 weight portion leucocianidol 5-7 weight portion cichoriin 2-4 weight portion anonaine 2-3 weight portion.
2. a kind of pharmaceutical composition for the treatment of malignant tumor according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Coreopsis basalis chalcone derivative 130 weight portion Ramulus seu Fructus Caesalpiniae 110 weight portion ZANGJINJIER 90 weight portion leucocianidol 6 weight portion cichoriin 3 weight portion anonaine 2.5 weight portion.
3. a kind of pharmaceutical composition for the treatment of malignant tumor according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of malignant tumor according to claim 1, is characterized in that the treatment malignant tumor medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of malignant tumor, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Coreopsis basalis chalcone derivative 120-140 weight portion Ramulus seu Fructus Caesalpiniae 100-120 weight portion ZANGJINJIER 80-100 weight portion leucocianidol 5-7 weight portion cichoriin 2-4 weight portion anonaine 2-3 weight portion;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
6. a kind of preparation method for the treatment of the pharmaceutical composition of malignant tumor according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Coreopsis basalis chalcone derivative 130 weight portion Ramulus seu Fructus Caesalpiniae 110 weight portion ZANGJINJIER 90 weight portion leucocianidol 6 weight portion cichoriin 3 weight portion anonaine 2.5 weight portion;
Preparation method: get Ramulus seu Fructus Caesalpiniae by crude drug proportioning, ZANGJINJIER, Coreopsis basalis chalcone derivative, leucocianidol, cichoriin, anonaine, mixing, with weight percent concentration 30% ethanol as solvent, extract at 45 DEG C of warm macerating, extraction time is 4 times, each extraction time is 3 hours, each solvent load is 20 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution, extracting solution reclaims ethanol, be concentrated into relative density 1.12, filter, medicinal liquid is by NKA-9 macroporous adsorptive resins, first wash with water, use the alcoholic solution eluting NKA-9 macroporous adsorptive resins of weight percent concentration 60% again, collect weight percent concentration 60% ethanol elution, reclaim ethanol, concentrate drying, obtain pharmaceutical composition.
7. a kind of preparation method for the treatment of the pharmaceutical composition of malignant tumor according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of malignant tumor according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats malignant tumor medicine.
CN201510871934.7A 2015-12-03 2015-12-03 Medicine composition for treating malignant tumors and preparing method thereof Withdrawn CN105326889A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510871934.7A CN105326889A (en) 2015-12-03 2015-12-03 Medicine composition for treating malignant tumors and preparing method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510871934.7A CN105326889A (en) 2015-12-03 2015-12-03 Medicine composition for treating malignant tumors and preparing method thereof

Publications (1)

Publication Number Publication Date
CN105326889A true CN105326889A (en) 2016-02-17

Family

ID=55277795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510871934.7A Withdrawn CN105326889A (en) 2015-12-03 2015-12-03 Medicine composition for treating malignant tumors and preparing method thereof

Country Status (1)

Country Link
CN (1) CN105326889A (en)

Similar Documents

Publication Publication Date Title
CN104840510A (en) Composition used for protecting gastric mucosa and application thereof
CN101850032B (en) Anti-tumor traditional Chinese medicine composition and preparation method and application thereof
CN104491342A (en) Medicament for treating diabetes and preparation method thereof
CN111494360B (en) Application of epimedin C in medicine for treating diabetic liver injury
CN104906251A (en) Traditional Chinese medicine compound combination with diabetes treating effect and preparation method and application thereof
CN108403818B (en) Composition for assisting in reducing blood sugar and application thereof
CN105535391A (en) Medicine composition for treating pneumonia
CN105497096A (en) Medicine composition for treating liver ascites and preparation method thereof
CN111375035A (en) Preparation and application of enteric-coated preparation for treating cervical spondylosis
CN112274586B (en) Chinese herbal compound preparation for treating hepatic fibrosis and preparation method and application thereof
CN104887760A (en) Ganoderma spore powder wine and preparation method thereof
CN113350390A (en) Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof
CN105326889A (en) Medicine composition for treating malignant tumors and preparing method thereof
CN105168300A (en) Pharmaceutical composition for treating diabetes and preparation method thereof
CN105287865A (en) Medicinal composition for treating malignant tumor
CN105287921A (en) Medicinal composition for treating gastric cancer and preparation method thereof
CN105535044A (en) Medicine composition for preventing and treating encephalatrophy
CN105456734A (en) Traditional Chinese medicine for treating diabetes
CN104352672A (en) Tortoise plastron-containing traditional Chinese medicine composition for treating diabetes
CN104056207B (en) Traditional Chinese medicine combination for treating stomach cancer and preparation method for same
CN116942771B (en) Traditional Chinese medicine composition for treating coronary heart disease and application thereof
CN102698096B (en) Composition of traditional Chinese medicine extracts and preparation method and application thereof
CN108542965B (en) Burdock root honey tablets and preparation method and application thereof
CN105125711A (en) Pharmaceutical composition for treating diabetic encephalopathy
CN104840747A (en) Traditional Chinese medicine composition capable of resisting thyroid cancer activity and preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160217